Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244603 | 0.85 | HSD11B1 (0.64) | HSD11B1KMT2AMGLLMEN1 | |
| SCHEMBL14269013 | 0.84 | KMT2A (0.64) | HSD11B1KMT2ACPB1MGLLMEN1 | |
| SCHEMBL2556107 | 0.82 | CPB1 (0.67) | HSD11B1KMT2ACPB1MGLLMEN1 | |
| SCHEMBL5214742 | 0.80 | HSD11B1 (0.67) | HSD11B1KMT2AMGLLALDH1A1HTR2A | |
| SCHEMBL1720183 | 0.80 | MGLL (0.82) | HSD11B1KMT2ACPB1MGLLMEN1 | |
| SCHEMBL5207580 | 0.79 | HSD11B1 (0.65) | HSD11B1KMT2AMGLLMEN1ALDH1A1 | |
| SCHEMBL7330630 | 0.79 | CPB1 (0.63) | HSD11B1KMT2ACPB1MGLLMEN1 | |
| SCHEMBL1720793 | 0.79 | HSD11B1 (0.81) | HSD11B1KMT2ACPB1MGLLMEN1 | |
| SCHEMBL571141 | 0.78 | KDM1A (0.60) | HSD11B1ALDH1A1RIPK1KDM1A | |
| SCHEMBL2202147 | 0.77 | ALDH1A1 (0.60) | HSD11B1KMT2ACPB1MGLLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | HSD11B1 1/4885KMT2A 1395/4885CPB1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.